Contents
pdf Download PDF
pdf Download XML
112 Views
31 Downloads
Share this article
Research Article | Volume 18 Issue 11 (November, 2026) | Pages 392 - 398
Comparison of Left Ventricular Global Longitudinal Strain Between Diabetic Patients With And Without Microalbuminuria
 ,
 ,
 ,
 ,
 ,
1
Postgraduate Resident, Department of Medicine, Ayub Teaching Hospital, Abbottabad, Pakistan
2
Consultant Interventional Cardiologist, Department of Cardiology, Kishwar Sultana Hospital and Cardiac Complex, Lahore, Pakistan
3
Consultant Cardiologist, DHQ Hospital, Nankana Sahib, Population and Health Department, Government of Punjab, Pakistan
4
Cardic Imaging (Non-Invasive) Department, SICVD, Larkana, Pakistan
5
Consultant Interventional Cardiologist, Cardiology/Cath Lab, Baba Bulleh Shah DHQ Hospital, Kasur, Pakistan
6
Consultant Cardiologist, Department of Cardiology, Jinnah Institute of Cardiology, Lahore, Pakistan
Under a Creative Commons license
Open Access
Received
Aug. 12, 2026
Revised
Oct. 22, 2026
Accepted
Nov. 5, 2026
Published
Nov. 17, 2026
Abstract

Microalbuminuria is an acknowledged indicator of renal microvascular damage in diabetes mellitus, and this phenomenon could be related to subclinical myocardial dysfunction. Left ventricular global longitudinal strain (LV-GLS) is a tool that can be used to identify subtle abnormalities in left ventricular systolic function despite normal left ventricular ejection fraction. Objective: To compare LV-GLS between diabetic patients with and without microalbuminuria. Methods: This comparative cross-sectional study was conducted at Ayub Teaching Hospital, Abbottabad, from December 2025 to May 2026. A study using 176 patients with type 2 diabetes mellitus, including 88 patients with microalbuminuria and 88 without microalbuminuria, was conducted. Two-dimensional speckle tracking echocardiography was used for assessment of LV-GLS. Group comparisons were conducted, correlation analysis was performed, and multivariable linear regression was done. Results: Patients with microalbuminuria had significantly lower mean LV-GLS compared with patients without microalbuminuria (p<0.001). The level of urinary albumin-to-creatinine ratio was significantly correlated with LV-GLS (p<0.001). After adjusting for potential confounding factors, microalbuminuria was still associated with impaired LV-GLS (p=0.013). Conclusion: Microalbuminuria was present in this analysis, and it was associated with a reduced LV-GLS, even in cases with preserved EF, suggesting a possible link between renal microvascular damage and subclinical myocardial dysfunction.

Keywords
INTRODUCTION

Diabetes mellitus (DM) is a huge public health problem with significant cardiovascular morbidity, mortality, and healthcare costs worldwide.[1] Diabetes mellitus (DM) is a huge public health problem with significant cardiovascular morbidity, mortality, and healthcare costs worldwide.[2]  The International Diabetes Federation estimates that in 2024, around 589 million adults, aged 20-79 years, were living with diabetes around the world, and the figure would rise to 853 million by 2050.[3] Cardiovascular disease is still a predominant cause of morbidity and mortality in diabetic patients, and frequently myocardial dysfunction occurs before the onset of clinically apparent heart failure.[4] The diabetic myocardium undergoes progressive structural and functional changes due to chronic hyperglycemia, insulin

 

resistance, oxidative stress, myocardial fibrosis, and microvascular dysfunction.[5] These changes can be present despite normal left ventricular ejection fraction (LVEF); hence, early recognition of subclinical cardiac dysfunction may be especially important in diabetics.

 

The other important microvascular complication of diabetes is diabetic kidney disease, and albuminuria is an established marker of kidney damage as well as higher cardiovascular risk.[6] Microalbuminuria, which is now considered moderately increased albuminuria (A2), is usually defined as a urinary albumin-to-creatinine ratio (UACR) of 30 to 300mg/g.[7] The prevalence of chronic kidney disease is higher in people with diabetes, around 20-40%, although this varies by diabetes type, diabetes duration, and the characteristics of the population.[8] In addition to renal implications, microalbuminuria is indicative of generalized endothelial dysfunction, increased vascular permeability, and systemic microvascular injury.[9] These pathophysiological changes can also result in coronary microcirculatory changes, leading to myocardial ischemia, relaxation defects, and early ventricular dysfunction.[9] Therefore, microalbuminuria could be a marker of diabetic patients who have a greater risk of cardiovascular abnormalities even if they don't have any cardiac symptoms.[10]

 

Two-dimensional speckle-tracking echocardiographic analysis of the left ventricle has yielded a sensitive parameter to assess myocardial systolic performance, called left ventricular global longitudinal strain (LV-GLS).[11] The LV-GLS differs from traditional LVEF because this parameter does not reflect impaired myocardial function in the early stage of myocardial dysfunction and can detect subtle myocardial dysfunction.[12] Myocardial fibers, especially those in the subendocardial area, are more vulnerable to ischaemia, fibrosis, and metabolic disturbances in diabetes.[5] The severity of GLS is generally reported as a negative percentage; the more negative the percentage, the more impaired the longitudinal systolic function.[13] Myocardial strain assessment has recently gained significant research interest in cardiac imaging for the detection of subclinical cardiac dysfunction and heart risk stratification in metabolic diseases and cardiovascular disorders.[14]

 

Microalbuminuria is associated with adverse cardiovascular outcomes, but it is not known if microalbuminuria is associated with impaired LV-GLS among diabetic patients in a clinically relevant manner. Standard echocardiographic parameters might not detect early myocardial changes, especially if the LVEF is normal in asymptomatic patients. Comparisons of LV-GLS in diabetics with and without MKM may therefore help to assess whether there is any measurable myocardial mechanics impairment associated with renal microvascular injury. The purpose of the present study was to assess LVGLS in diabetic patients with and without microalbuminuria to see if there is increased subclinical LVSD in patients with microalbuminuria. The findings may contribute to improved cardiovascular risk stratification and provide evidence regarding the potential role of LV-GLS in the early cardiac evaluation of diabetic patients.

MATERIALS AND METHODS

This is a comparative cross-sectional study to compare the LV-GLS in diabetic patients with and without microalbuminuria. The study was carried out in the Department of Cardiology, Ayub Teaching Hospital, Abbottabad, Pakistan, and the hospital laboratory for assessment of urinary albumin excretion. The study lasted six months, between 1st December 2025 and 31st May 2026.

The sample size was determined using the OpenEpi version 3.01 sample size calculator for comparison of two independent means, with a 95% confidence level, 80% statistical power, and a ratio of allocation of 1:1. The minimum sample size was calculated based on the mean values of LV-GLS obtained in a previous study, with a minimum requirement of 158 patients (79 patients in each group).[15] With about 10% incomplete data or technically inadequate echocardiographic measurements, the final target sample size was raised to 176 patients, including 88 diabetic patients with microalbuminuria and 88 diabetic patients without microalbuminuria.

 

Patient recruitment was done using a non-probability consecutive sampling technique. Patients who were referred to the Department of Cardiology throughout the study period were screened, and those who met the inclusion criteria were included. Patients were divided into two groups based on their urinary albumin-to-creatinine ratio (UACR): the first with an elevated UACR and the second with a normal one. The diabetic patients of Group A were those having microalbuminuria and Group B were those without microalbuminuria. Recruitment was done until adequate numbers were met within each group.

Patients were adults aged 18 to 75 years with already established type 2 diabetes mellitus. Patients were included regardless of gender, provided they had a known urinary albumin-creatinine ratio (ACR) and an ejection fraction of at least 50% as assessed by conventional echocardiogram. Patients with UACR ranging from 30 to 300 mg/g were defined as having microalbuminuria, and those with levels below 30 mg/g as normoalbuminuria.[16] Patients were included if they were clinically stable, the echocardiogram was of good quality to allow speckle-tracking analysis, and informed consent was given.

 

Patients were excluded if they had either ischemic heart disease, myocardial infarction, coronary revascularization, symptomatic heart failure, significant valvular heart disease, congenital heart disease, or had an established cardiomyopathy. Excluded patients also included those with left ventricular ejection fraction less than 50 percent, persistent arrhythmias, uncontrolled hypertension, advanced chronic kidney disease (CKD), and macroalbuminuria (UACR greater than 300 mg/g). Those with known non-diabetic renal disease, active UTI, acute systemic illness, or other conditions likely to result in transient albuminuria were excluded. Patients who did not have a good echocardiographic acoustic window for reliable LV-GLS measurements were excluded.

 

Following approval from the institutional ethical review committee and obtaining informed consent, eligible patients were enrolled according to the predefined selection criteria. The data collected were demographic and clinical data, which included age, sex, BMI, history of diabetes mellitus, smoking status, and antidiabetic medications used, recorded by a structured data collection form. Relevant laboratory parameters such as glycated hemoglobin (HbA1c), serum creatinine, estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio (UACR) were recorded. Spot urine samples were used for urinary albumin excretion, and patients were categorized by UACR value. If available, repeated UACR measurements were reviewed to avoid misclassification and to obtain persistent albuminuria.

 

The participants all had a transthoracic echocardiogram on a standard imaging protocol. Parameters of traditional echocardiographic measurements were evaluated, such as left ventricular end-diastolic diameter, left ventricular end-systolic diameter, interventricular septal thickness, posterior wall thickness, left ventricular ejection fraction, and pertinent indices of diastolic function. Left ventricular ejection fraction was determined using the modified biplane Simpson's method. Two-dimensional speckle tracking echocardiography was then performed in the standard apical four-chamber, two-chamber, and three-chamber views.

 

During acquisition, adequate electrocardiographic gating and image quality were provided. The available strain measurement software was used for myocardial deformation analysis, and LV-GLS was taken as the average of the LV myocardial segments' longitudinal strain measurements. The average values of the LV-GLS were reported as a percentage, with lower scores reflecting poorer longitudinal systolic function. Echocardiographic data were documented and analyzed in the presence and absence of microalbuminuria in diabetic patients.

 

The data were coded and analysed on IBM SPSS Statistics. Normality of continuous variables was evaluated by the Shapiro–Wilk test and by visualizing data distributions. Quantitative variables (age, BMI, duration of diabetes, HbA1c, UACR, LVEF, LV-GLS) were presented as mean ± SD for normally distributed variables and median (IQR) for non-normally distributed variables. Frequencies and percentages were used to present categorical variables such as sex, hypertension, smoking, and medication. The independent-samples t-test was performed to compare mean LV-GLS between diabetic patients with and without microalbuminuria when the data were normally distributed, whereas the Mann–Whitney U test was used when the data were not normally distributed. The chi-square test was used to compare categorical variables as appropriate. Multivariable linear regression analysis was conducted to determine whether microalbuminuria was independently associated with LV-GLS while controlling for model assumptions and sample size adequacy, and adjusting for potential confounding variables: age, sex, BMI, duration of diabetes, hypertension, and HbA1c. A two-sided p-value of less than 0.05 was considered statistically significant.

 

RESULTS

A total of 176 patients with type 2 diabetes mellitus were included in the analysis, comprising 88 patients with microalbuminuria and 88 without microalbuminuria. The groups did not significantly differ with regard to age, sex distribution, BMI, smoking status, heart rate, or treatment with antidiabetic drugs. Patients with microalbuminuria, however, had a significantly longer duration of diabetes, higher prevalence of hypertension, and higher SBP and DBP (p<0.05). (Table 1)

 

Laboratory findings showed significantly higher HbA1c levels (8.7 ± 1.4% vs. 7.9 ± 1.3%, p<0.001) and serum creatinine levels (1.04 ± 0.20 vs. 0.95 ± 0.18 mg/dL, p=0.002) among patients with microalbuminuria. Estimated glomerular filtration rate was significantly lower in this group (79.5 ± 14.6 vs. 86.1 ± 13.8 mL/min/1.73 m², p=0.002). Median urinary albumin-creatinine ratio was also significantly elevated (86 vs. 12 mg/g, p<0.001). (Table 2)

 

Patients with microalbuminuria had significantly thicker interventricular septal and posterior walls in a conventional echocardiographic evaluation. Diastolic function was also different, with these patients having a lower E/A ratio and a higher average E/e′ ratio. No significant differences were found between groups regarding left ventricular dimensions and ejection fraction (p>0.05). (Table 3)

 

The primary outcome analysis demonstrated significantly impaired LV-GLS among patients with microalbuminuria compared with those without microalbuminuria (−15.5 ± 2.7% vs. −17.1 ± 2.6%, p<0.001). The mean difference between groups was 1.6 percentage points (95% CI: 0.81–2.39). Left ventricular ejection fraction was ≥ 50% for all participants. (Table 4)

LV-GLS was highly correlated with urinary albumin-to-creatinine ratio (ρ=0.32, p<0.001), diabetes duration (r=0.29, p<0.001) and HbA1c (r=0.27, p<0.001). Strong negative correlations with estimated GFR (r=−0.18, p=0.017) and LVEF (r=−0.24, p=0.001) were found. There was no statistically significant relationship between BMI and LV-GLS. (Table 5)

Multivariable linear regression analysis showed that after controlling for age, sex, BMI, diabetes duration, hypertension, and HbA1c, microalbuminuria was still significantly associated with less negative LV-GLS (adjusted B=0.95, 95% CI: 0.20–1.70, p=0.013). Longer diabetes duration (B=0.075, p=0.020) and higher HbA1c levels (B=0.22, p=0.041) were also significantly associated with impaired LV-GLS, whereas age, sex, body mass index, and hypertension were not statistically significant predictors. (Table 6)

 

 

 

Table 1. Demographic and clinical characteristics

Variable

Microalbuminuria

(n=88)

No microalbuminuria

(n=88)

p-value

Age (years), mean ± SD

56.8 ± 9.4

54.9 ± 10.1

0.199

Male sex, n (%)

49 (55.7)

46 (52.3)

0.650

Female sex, n (%)

39 (44.3)

42 (47.7)

 

BMI (kg/m²), mean ± SD

28.6 ± 3.9

27.8 ± 3.7

0.165

Diabetes duration (years), mean ± SD

10.7 ± 5.1

7.9 ± 4.6

<0.001

Hypertension, n (%)

47 (53.4)

31 (35.2)

0.015

Current smoking, n (%)

18 (20.5)

15 (17.0)

0.559

Systolic BP (mmHg), mean ± SD

136.2 ± 15.4

130.5 ± 14.8

0.013

Diastolic BP (mmHg), mean ± SD

82.6 ± 9.1

79.9 ± 8.7

0.046

Heart rate (beats/min), mean ± SD

78.4 ± 10.2

76.8 ± 9.6

0.285

Oral antidiabetic drugs, n (%)

52 (59.1)

61 (69.3)

0.158

Insulin-containing regimen, n (%)

36 (40.9)

27 (30.7)

0.158

 

Table 2. Laboratory and renal parameters

Variable

Microalbuminuria

(n=88)

No microalbuminuria \(n=88)

p-value

HbA1c (%), mean ± SD

8.7 ± 1.4

7.9 ± 1.3

<0.001

Serum creatinine (mg/dL), mean ± SD

1.04 ± 0.20

0.95 ± 0.18

0.002

eGFR (mL/min/1.73 m²), mean ± SD

79.5 ± 14.6

86.1 ± 13.8

0.002

UACR (mg/g), median (IQR)

86 (52–157)

12 (7–19)

<0.001

 

Table 3. Conventional echocardiographic parameters

Variable

Microalbuminuria (n=88)

No microalbuminuria (n=88)

p-value

LV end-diastolic diameter (mm)

48.7 ± 4.3

47.9 ± 4.1

0.208

LV end-systolic diameter (mm)

31.2 ± 3.6

30.4 ± 3.5

0.137

Interventricular septal thickness (mm)

10.8 ± 1.4

10.2 ± 1.3

0.004

Posterior wall thickness (mm)

10.5 ± 1.2

10.0 ± 1.2

0.006

LVEF (%), biplane Simpson

59.1 ± 4.8

60.4 ± 4.6

0.069

E/A ratio

0.88 ± 0.22

0.96 ± 0.24

0.023

Average E/e′ ratio

10.9 ± 2.8

9.8 ± 2.5

0.007

 

Table 4. Primary outcome: left ventricular global longitudinal strain

Outcome

Microalbuminuria

(n=88)

No microalbuminuria (n=88)

p-value/95% CI

LV-GLS (%), mean ± SD

−15.5 ± 2.7

−17.1 ± 2.6

p < 0.001

Difference in mean GLS

(micro − no micro)

+1.6 percentage points

Reference

+0.81 to +2.39

LVEF ≥50%, n (%)

88 (100)

88 (100)

Eligibility criterion

 

Table 5. Associations with LV-GLS in the overall sample (n=176)

Predictor

Correlation coefficient (r or ρ)

p-value

UACR (mg/g), Spearman ρ

+0.32

<0.001

Age (years), Pearson r

+0.15

0.047

BMI (kg/m²), Pearson r

+0.11

0.146

Diabetes duration (years), Pearson r

+0.29

<0.001

HbA1c (%), Pearson r

+0.27

<0.001

eGFR, Pearson r

−0.18

0.017

LVEF (%), Pearson r

−0.24

0.001

 

 

Table 6. Multivariable linear regression for LV-GLS (n=176)

Predictor

Adjusted B (GLS percentage points)

95% CI

p-value

Microalbuminuria (yes vs no)

+0.95

+0.20 to +1.70

0.013

Age (per year)

+0.025

−0.012 to +0.062

0.185

Male sex (vs female)

+0.18

−0.48 to +0.84

0.593

BMI (per kg/m²)

+0.045

−0.045 to +0.135

0.327

Diabetes duration (per year)

+0.075

+0.012 to +0.138

0.020

Hypertension (yes vs no)

+0.38

−0.31 to +1.07

0.280

DISCUSSION

The present study demonstrated significantly impaired left ventricular global longitudinal strain (LV-GLS) among patients with type 2 diabetes mellitus and microalbuminuria compared with those without microalbuminuria, despite preserved left ventricular ejection fraction (LVEF). In patients with microalbuminuria, mean LV-GLS was −15.5±2.7%, whereas in those without microalbuminuria it was −17.1 ± 2.6% (p<0.001). This difference indicated an association between urinary albumin excretion and subclinical myocardial dysfunction. The results were similar to the TESEO study published in 2025 that involved 193 patients with type 2 diabetes, which found that patients with albuminuria had less negative GLS values. Association of impaired GLS with albuminuria was not confounded by other cardiovascular and clinical risk factors. The direction of the association was similar, but there were differences in the study populations, glycemic control, and distribution of albuminuria that might be taken into account when interpreting the magnitude of the findings.[17]

 

In a 2022 study published in the Journal of Cardiovascular Echography, 60 normotensive patients with type 2 diabetes were compared equally by albuminuria status. The investigators found a mean LV-GLS of −15.57 ± 2.77% in the patients with albuminuria compared to −16.79 ± 2.70% in the non-albuminuric patients. These values were similar to the ones found in this study, but the difference between the groups in the previous study was not significant (p=0.077). Within the albuminuric population, however, there was a significant correlation between the albumin-to-creatinine ratio and GLS (r=0.55, p=0.002). The difference in statistical significance may partly reflect the smaller sample size and restriction to normotensive patients in the previous investigation.[18]

 

In the present analysis, patients with microalbuminuria were also associated with higher HbA1c levels, longer duration of diabetes, and a higher prevalence of hypertension. These features could have led to intergroup variations of myocardial deformation. A 2023 controlled cross-sectional study of 75 diabetic patients and 75 controls found decreased LV-GLS in diabetic patients (mean of −17.02 ± 3.06%). There were statistically significant associations between GLS and systolic blood pressure, diastolic blood pressure, fasting plasma glucose

 

and HbA1c. These observations highlighted the relevance of metabolic and hemodynamic characteristics in assessing myocardial strain in diabetic population. The prior study, however, did not stratify patients based on albuminuria but compared diabetics with nondiabetics.[19]

 

A study in 2023 using cardiovascular magnetic resonance in patients with type 2 diabetes and preserved ejection fraction also demonstrated an association between glycemic control and LV-GLS. The investigators found a lower GLS for diabetic patients than for controls (−16.51 ± 2.53% versus −19.66 ± 3.21%, p<0.001). Patients with diabetes and hypertension had greater strain impairment than normotensive diabetic patients; the impairment of myocardial deformation was significantly predicted by HbA1c alone. The same is true for the present regression analysis, which confirmed that HbA1c was a significant correlate of LV-GLS. However, direct comparison of numbers was limited as the previous study employed cardiac magnetic resonance feature tracking instead of 2-D speckle tracking echocardiography.[20]

 

A further study was published in Clinical Cardiology in 2023 that examined the association of HbA1c with LV-GLS in patients with type 2 diabetes. The investigators found that, after multivariable adjustment, higher levels of HbA1c are independently associated with lower absolute GLS magnitude. This same finding was also observed in the present analyses, where HbA1c was also significantly correlated with less negative LV-GLS values (adjusted B=0.22, p=0.041). Association in cross-sectional analysis, however, did not reveal whether poor glycemic control led to myocardial dysfunction, or whether the association was simply due to an increased overall burden of diabetes-related complications.[21]

 

Another important finding was that the differences in LV-GLS did not affect the preservation of conventional LVEF. Three-dimensional echocardiographic (3D-ECHO) analysis of myocardial strain revealed a progressive decline in longitudinal strain in 40 patients with diabetes, 35 with prediabetes and 33 healthy controls in 2023. The reported absolute three-dimensional GLS values were 18.64 ± 2.43%, 15.21 ± 1.49%, and 13.49 ± 2.36%, respectively. HbA1c and BMI were also found to be independent factors associated with subclinical LV dysfunction. This observation that the strain measure was different in spite of the preserved LVEF was broadly consistent with the present results. In the present analysis, however, BMI was not significantly related to LV-GLS, which highlights the fact that different individual predictors can differ in different populations and statistical models.[22]

 

The present study additionally demonstrated a lower E/A ratio, higher E/e′ ratio, and greater ventricular wall thickness among patients with microalbuminuria. The results indicated that there were also some accompanying differences in ventricular relaxation and cardiac structure. A cross-sectional study in 2024 of 134 type 2 diabetes patients in central Vietnam demonstrated that those with type 2 diabetes had higher LV mass and interventricular septal thickness compared to controls, but normal conventional LVEF. While that investigation focused mainly on the function of the left atrium, and was not a direct comparison of the albuminuria groups, the structural findings are relevant to the echocardiographic differences seen in this analysis.[23]

 

Results were generally similar to those recently reported, showing abnormalities of myocardial deformation in diabetes patients, especially those with albuminuria, suboptimal glucose control and other cardiovascular risk factors. The association between microalbuminuria and LV-GLS was adjusted, which showed that the difference between microalbuminuria and LV-GLS was not fully accounted for by the covariates used in the regression model. Causal interpretations were however limited due to the residual confounding, unequal strain measurement methods and the cross-sectional study design. Additionally, the results did not demonstrate whether or not a clinical benefit would be seen with routine LV-GLS surveillance in patients with microalbuminuria. Prospective studies would be needed to establish the prognostic importance of these associations.

 

LIMITATIONS

There were some limitations in the present study. The results were limited to the specific setting of a single center design, which made the conclusions difficult to generalize, and it did not allow for causal inferences between microalbuminuria and impaired LV-GLS. Selection bias may have been taken into account in this study because it was based on a non-probability sampling technique, the consecutive sampling technique. Multivariable analysis was performed to compensate for the potential confounding variables, but residual confounding due to unmeasured clinical and treatment related variables was not eliminated. In addition, the lack of long-term follow-up did not allow for evaluation of the predictive value of LV-GLS and its association with further cardiovascular events.

CONCLUSION

Among the diabetic patients, those who had microalbuminuria had a significantly poorer left ventricular global longitudinal strain than those without microalbuminuria despite normal left ventricular ejection fraction. After taking into account the clinical factors, microalbuminuria was still independently associated with less negative LV-GLS values. The results indicated that in patients with type 2 diabetes mellitus, microalbuminuria may be a predictor of subclinical LVSD (left ventricular systolic dysfunction). LV-GLS evaluation can give additional information when assessing the cardiovascular system, but there is a need for larger prospective studies to define the prognostic and clinical value of LV-GLS.

REFERENCES
  1. Hossain, M.J., M. Al‐Mamun, and M.R. Islam, Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health science reports, 2024. 7(3): p. e2004.
  2. Siam, N.H., et al., Diabetes mellitus and cardiovascular disease: exploring epidemiology, pathophysiology, and treatment strategies. Reviews in cardiovascular medicine, 2024. 25(12): p. 436.
  3. Genitsaridi, I., et al., of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. The Lancet Diabetes & Endocrinology, 2026. 14(2): p. 149-156.
  4. Seferović, P.M., et al., Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases. European Journal of Heart Failure, 2024. 26(9): p. 1893-1903.
  5. Pan, K.-L., et al., The role of cardiac fibrosis in diabetic cardiomyopathy: from pathophysiology to clinical diagnostic tools. International journal of molecular sciences, 2023. 24(10): p. 8604.
  6. Jha, R., et al., Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions. Biomedicines, 2024. 12(5): p. 1098.
  7. Izarra, A., et al., Baseline and 4‐year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort. Diabetes, Obesity and Metabolism, 2026. 28(5): p. 3777-3787.
  8. Pavkov, M.E., et al., Kidney disease and diabetes. Diabetes in America [Internet], 2024.
  9. Hang, X., et al., Renal microcirculation and mechanisms in diabetic kidney disease. Frontiers in endocrinology, 2025. 16: p. 1580608.
  10. Barzilay, J.I., Y.M. Farag, and J. Durthaler, Albuminuria: an underappreciated risk factor for cardiovascular disease. Journal of the American Heart Association, 2024. 13(2): p. e030131.
  11. Gherbesi, E., et al., Myocardial strain of the left ventricle by speckle tracking echocardiography: From physics to clinical practice. Echocardiography, 2024. 41(1): p. e15753.
  12. Tavernese, A., et al., Early echocardiographic markers in heart failure with preserved ejection fraction. Journal of Cardiovascular Development and Disease, 2025. 12(6): p. 229.
  13. Lu, S., et al., Post-systolic shortening is superior to global longitudinal strain in predicting adverse events in patients with stable coronary artery disease and preserved systolic function. Insights into Imaging, 2022. 13(1): p. 35.
  14. Gao, L., et al., Clinical utility of strain imaging in assessment of myocardial fibrosis. Journal of clinical medicine, 2023. 12(3): p. 743.
  15. Abdellatif, Y.A., et al., A Subtle Decline in Cardiac Mechanics is correlated with Albuminuria in Asymptomatic Normotensive Patients with Type 2 Diabetes Mellitus: A Two Dimensional Strain Echocardiography Study. Journal of Cardiovascular Echography, 2022. 31(4): p. 220.
  16. Verma, A., et al., Association of albuminuria with chronic kidney disease progression in persons with chronic kidney disease and normoalbuminuria: a cohort study. Annals of internal medicine, 2024. 177(4): p. 467-475.
  17. Barutta, F., et al., Albuminuria is independently associated with preclinical left ventricular systolic dysfunction: The TESEO study. World J Diabetes, 2025. 16(9): p. 106914.
  18. Abdellatif, Y.A., et al., A Subtle Decline in Cardiac Mechanics is correlated with Albuminuria in Asymptomatic Normotensive Patients with Type 2 Diabetes Mellitus: A Two Dimensional Strain Echocardiography Study. J Cardiovasc Echogr, 2021. 31(4): p. 220-226.
  19. Trang, N.N., N.A. Vu, and L. Van Chi, Association Between Left Ventricular Strains and Cardiovascular Risk Factors in Type 2 Diabetic Patients: a Controlled Cross-sectional Study. Acta Inform Med, 2023. 31(3): p. 216-221.
  20. Li, Z., et al., Hemoglobin A1c in type 2 diabetes mellitus patients with preserved ejection fraction is an independent predictor of left ventricular myocardial deformation and tissue abnormalities. BMC Cardiovasc Disord, 2023. 23(1): p. 49.
  21. Gao, J., et al., Left ventricular longitudinal strain in patients with type 2 diabetes mellitus is independently associated with glycated hemoglobin level. Clinical Cardiology, 2023. 46(12): p. 1578-1587.
  22. Wu, T., et al., Three-dimensional echocardiography and strain cardiac imaging in patients with prediabetes and type 2 diabetes mellitus. Quant Imaging Med Surg, 2023. 13(12): p. 7753-7764.
  23. Dang, H.N.N., T.V. Luong, and T.T. Tran, Evaluating left atrial function changes by speckle tracking echocardiography in type 2 diabetes patients in Central Vietnam: a cross-sectional comparative study. The Egyptian Heart Journal, 2024. 76(1): p. 38.

 

Recommended Articles
Research Article
Comparison of Systemic Immune-Inflammation Index and Neutrophil-to-Lymphocyte Ratio for Identifying High Disease Activity in Rheumatoid Arthritis
...
Published: 19/11/2026
Research Article
Clinical Evaluation of Postoperative Nausea and Vomiting Among Patients Undergoing General Anaesthesia.
Published: 25/12/2019
Research Article
Antimicrobial Resistance in Complicated Urinary Tract Infections: A Retrospective Study in a Tertiary Care Hospital of Western Odisha
...
Published: 19/11/2026
Research Article
Geriatric Neurosurgery: Need of Developing A Practice Protocol-Experience In A Tertiary Care Hospital Of Western Odisha
...
Published: 18/11/2026
Chat on WhatsApp
© Copyright CME Journal Geriatric Medicine